PCN17 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, UK AND ITALY- BEVACIZUMAB (BEV) INTERFERON-ALPHA2A COMPARED WITH SUNITINIB
Abstract
Authors
GH Mickisch B Escudier M Gore G Procopio S Walzer MJ Nuijten